We predicted that drugs which interact with EGFR (Erlotinib, Crizotinib, and Lapatinib), estrogen signalling (Tamoxifen, Fulvestrant, Hydrocortisone, and Anastrozole) and TRAIL-mediated apoptosis (Azithromycin and Anastrozole) pathways have potential for treating ESCC. The gene discussed is EGFR; the disease is esophageal squamous cell carcinoma.